|
End-of-day quote
Shanghai S.E.
2026-09-01
|
5-day change | 1st Jan Change | ||
| 18.41 CNY | -0.22% |
|
+6.05% | +4.48% |
| 08-24 | DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 04-24 | Dashenlin Pharma's Q1 Profit Rises 11% | MT |
Company Valuation: DaShenLin Pharmaceutical Group Co., Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 33,307 | 37,585 | 28,359 | 17,151 | 20,066 | 20,966 | - | - |
| Change | - | 12.85% | -24.55% | -39.52% | 17% | 4.48% | - | - |
| Enterprise Value (EV) 1 | 32,838 | 36,233 | 27,369 | 15,778 | 16,831 | 17,626 | 17,206 | 16,911 |
| Change | - | 10.34% | -24.46% | -42.35% | 6.67% | 4.73% | -2.38% | -1.72% |
| P/E | 42.1x | 36.3x | 24.2x | 18.6x | 16.3x | 14.1x | 12.1x | 10.6x |
| PBR | 6.3x | 6.24x | 4.16x | 2.49x | 2.72x | 2.67x | 2.45x | 2.28x |
| PEG | - | 1.2x | 1.8x | -0.9x | 0.5x | 0.7x | 0.8x | 0.8x |
| Capitalization / Revenue | 1.99x | 1.77x | 1.16x | 0.65x | 0.73x | 0.71x | 0.64x | 0.58x |
| EV / Revenue | 1.96x | 1.71x | 1.12x | 0.6x | 0.61x | 0.59x | 0.53x | 0.47x |
| EV / EBITDA | 13.6x | 19.2x | 12.9x | 4.65x | 4.39x | 4.63x | 4.04x | 3.52x |
| EV / EBIT | 31.6x | 25.5x | 16.8x | 10.5x | 8.26x | 7.61x | 6.5x | 5.59x |
| EV / FCF | 117x | 13.1x | 19.7x | 9.51x | 3.44x | 10.2x | 6.16x | 5.2x |
| FCF Yield | 0.86% | 7.61% | 5.09% | 10.5% | 29.1% | 9.78% | 16.2% | 19.2% |
| Dividend per Share 2 | 0.3472 | 0.5 | 0.31 | 0.31 | 0.49 | 0.9418 | 1.043 | 1.222 |
| Rate of return | 1.19% | 1.52% | 1.24% | 2.06% | 2.78% | 5.12% | 5.66% | 6.64% |
| EPS 2 | 0.6944 | 0.9083 | 1.03 | 0.81 | 1.08 | 1.31 | 1.516 | 1.73 |
| Distribution rate | 50% | 55% | 30.1% | 38.3% | 45.4% | 71.9% | 68.8% | 70.6% |
| Net sales 1 | 16,759 | 21,248 | 24,531 | 26,497 | 27,502 | 29,630 | 32,727 | 36,225 |
| EBITDA 1 | 2,408 | 1,883 | 2,119 | 3,395 | 3,833 | 3,808 | 4,263 | 4,802 |
| EBIT 1 | 1,041 | 1,421 | 1,632 | 1,501 | 2,038 | 2,317 | 2,649 | 3,026 |
| Net income 1 | 791.2 | 1,036 | 1,166 | 914.8 | 1,235 | 1,493 | 1,728 | 1,969 |
| Net Debt 1 | -469.2 | -1,352 | -989.8 | -1,373 | -3,236 | -3,340 | -3,760 | -4,056 |
| Reference price 2 | 29.24 | 33.00 | 24.90 | 15.06 | 17.62 | 18.41 | 18.41 | 18.41 |
| Nbr of stocks (in thousands) | 1,138,968 | 1,138,947 | 1,138,902 | 1,138,848 | 1,138,848 | 1,138,848 | - | - |
| Announcement Date | 4/27/22 | 4/27/23 | 4/28/24 | 4/25/25 | 4/23/26 | - | - | - |
1CNY in Million2CNY
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 14.09x | 0.6x | 4.64x | 5.1% | 3.12B | |
| 16.69x | 0.67x | 10.01x | -.--% | 14.85B | |
| 16.9x | 0.76x | 7.93x | 2.2% | 6.43B | |
| 20.6x | 0.78x | 13.13x | 1.09% | 6.37B | |
| 14.62x | 0.9x | 6.22x | 3.05% | 4.13B | |
| 14.38x | 1.23x | 7.56x | 5.59% | 3.2B | |
| 13.67x | 0.82x | 6.16x | 4.69% | 2.88B | |
| 30.22x | - | - | - | 2.35B | |
| 20.28x | 0.59x | 7.57x | 2.03% | 1.51B | |
| Average | 17.94x | 0.79x | 7.90x | 2.97% | 4.98B | |
| Weighted average by Cap. | 17.37x | 0.77x | 8.87x | 1.98% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 603233 Stock
- Valuation DaShenLin Pharmaceutical Group Co., Ltd.
Select your edition
All financial news and data tailored to specific country editions
